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Advances in the discovery of a peripheral biomarker for the diagnosis of Alzheimer’s would provide a way to better detect the
onset of this debilitating disease in a manner that is both noninvasive and universally available. This paper examines the current
approaches that are being used to discover potential biomarker candidates available in the periphery. The search for a peripheral
biomarker that could be utilized diagnostically has resulted in an extensive amount of studies that employ several biological
approaches, including the assessment of tissues, genomics, proteomics, epigenetics, and metabolomics. Although a deﬁnitive
biomarker has yet to be conﬁrmed, advances in the understanding of the mechanisms of the disease and major susceptibility
factors have been uncovered and reveal promising possibilities for the future discovery of a useful biomarker.
1.Introduction
The incidence of Alzheimer’s disease (AD), the most preva-
lent form of dementia seen in the elderly population, is
expected to increase exponentially over the next ten years.
With the pervasive nature of such a debilitating disease,
extensive research has focused on potential peripheral
biomarkers and how they could be utilized to diagnose
and monitor the progress of Alzheimer’s disease. There are
two types of biomarkers: state markers and stage markers.
A state marker denotes the severity of the disease in the
individual. As the amount of a certain state marker increases,
the severity of the disease in the individual increases. Stage
markers indicate how far the disease has progressed within
the individual. If an individual has a certain degenerative
disease, then a state and stage marker will be present [1].
According to the Consensus Report of the Working Group
onMolecularandBiochemicalMarkersofAlzheimerDisease,
a biomarker must adhere to certain basic requirements,
including the ability to reﬂect AD pathology and diﬀeren-
tiate it from other dementia with an 80% sensitivity, be
reliable and reproducible, be easy to perform and analyze,
and remain relatively inexpensive [2]. Currently, the most
eﬀective methods for ascertaining the diagnosis of AD is
limited to imaging technology (e.g., MRI and PET) and the
analysis of cerebrospinal ﬂuid (CSF), which requires lumbar
puncture [3]. Ideally, both technologies have good speciﬁcity
and sensitivity but have limitations of expense and risks
associated with invasive procedures.
The discovery of a well-established peripheral biomarker
that is easily accessible and cost eﬀective is of primary
importance when considering the prevalence of this disease.
The necessity for a biomarker for AD in blood is so high
because of the disadvantages of the status quo. The above
consideration suggests the need for a diagnostic biomarker
able to detect disease prior to symptomatic onset. In order
to achieve this goal, such a diagnostic biomarker needs to
be one that could be part of a routine physical exam, as is
currently the case for lipid proﬁle. This implies a biomarker
that could be obtained in any physician’s oﬃce or specimen
collecting station with minimal invasiveness at reasonable
cost and time demand. In order to be adopted for wide
use, the biomarker has to have demonstrated consistency in
a large number of persons from a variety of populations.
Current imaging and CSF biomarker studies satisfy the
criteria of having been established in a large number of
persons and in a variety of populations. These studies have
served to establish the important principle of feasibility
of early detection. However, these classes of biomarker do
not satisfy the criteria of minimal invasiveness, reasonable2 International Journal of Alzheimer’s Disease
cost, or minimal time demand. These considerations lead
to a strong recommendation of the need for an eﬀective
biomarker of AD. The criteria of minimal invasiveness,
minimal time by the physician, and reasonable cost argue for
aneasilyobtainedsampleofperipheraltissuethatcouldthen
be analyzed either in the oﬃce or at a central location.
DiagnosisofADismademainlyfromclinicaltesting,and
currently, there is no completely accurate test for diagnosing
AD. Obtaining CSF from elderly individuals on repeated
occasions is no easy task. Blood is very easy to obtain, and
since CSF is absorbed into the blood every day, plasma can
supply numerous biomarkers for AD 4. Therefore, ﬁnding
a peripheral biomarker that uses easily collected samples
(e.g., plasma, blood, saliva, and urine) would be doubly
advantageous because of its relatively noninvasive procedure
and ability to provide an accurate diagnosis. The search to
ﬁnd a peripheral biomarker that could serve as a deﬁnitive
diagnostic tool that is universally available has created a vast
body of studies that spans over several diﬀerent biological
approaches. In this paper, we will examine the current status
of potential peripheral biomarkers of Alzheimer’s disease,
evaluating each from the perspective of being minimally
invasive, easily obtainable with a minimal time requirement
and reasonable cost. We will further evaluate each biomarker
from the perspectives of the ability to detect already diag-
nosed disease and ability to predict future disease.
2. EvaluableTissues
The widespread incidence of Alzheimer’s has seemingly no
pattern of “onset.” Because up to 98% of Alzheimer cases are
sporadic, it is crucial to identify potential biomarkers from
assessable tissues that could diagnose AD on an individual
basis [4]. The utility of such an approach is the availability of
bodily samples that could provide a noninvasive and rather
inexpensive process for diagnostic determination, such as a
swab of saliva, a simple blood sample, or a urine test.
The utilization of saliva as a biological marker of
AD has been examined and led to the possibility of its
utility in diagnosing early onset forms of the disease and
diﬀerentiating AD type dementia from other forms of
neurodegenerativeillnesses.Biopsiesofthesalivaryglandcan
produce signiﬁcant ﬁndings for Alzheimer’s, since salivary
epithelial cells express amyloid precursor protein and Aβ.
Also, it is important to note that changes in the cerebrospinal
ﬂuid may perhaps be reﬂected in the saliva [5]. One study
compared a group of individuals with AD to a group of
controls matched for age and sex as well as individuals with
Parkinson’s disease. The ﬁndings uncovered that there was
a small, but still statistically relevant, increase of Aβ42 in
patients with mild AD [5]. It should be noted that there
was no noticeable change in the Aβ42 levels of either the
controls of Parkinson’s patients, which would indicate that
the salivary levels of Aβ42 could be used to distinguish AD
from other forms of dementia. Studies also suggest there is a
connection between the salivary acetylcholinesterase enzyme
(AChE) and AD, since it is already established that a decrease
in central cholinergic activity is a noteworthy aspect of the
disease biochemistry [6]. During early stages, the cholinergic
neurons primarily undergo degeneration and result in a
notable decrease in acetylcholine. One study revealed that in
patients with AD, AChE activity was appreciably lower than
in their age-matched counterparts, suggesting that salivary
levels of cholinergic activity could be a biomarker [7]. The
changes in salivary AChE activity appear to parallel the
AD-associated decrease in brain cholinergic activity [7]. In
a study done by Sayer et al., subjects receiving treatment
with AChE inhibitors were classiﬁed based on whether they
responded cognitively to the AChE treatment. They found
a signiﬁcant diﬀerence in AChE levels between those who
did not respond to the treatment and their controls [7].
While these studies demonstrate the possible fronts through
which a useful biomarker can be found, there have yet
to be conclusive results verifying the diagnostic value of
acetylcholinesterase levels and whether peripheral salivary
markers truly reﬂect changes in cerebrospinal ﬂuid.
The use of blood as a tissue to yield potential biomarkers
of AD has both its advantages as well as challenges. The
most prominent challenge to determining the accuracy of
a blood biomarker is in establishing a correlation between
brain changes and dectecting those changes in blood [8].
Despite the diﬃculties presented by a blood-brain barrier,
the possibility of a blood protein signature and notable alter-
ations in blood-based proteins may present biomarkers that
could be used to predict and monitor disease progression.
Along with the ease of accessibility of blood, there is the
additional advantage of the multiple tissues present in blood,
namely, plasma, serum, and its cellular components (e.g.,
reds cells, white cells, and platelets).
The use of plasma-based proteins oﬀers some promising
risk analysis tools. Plasma is the liquid portion of blood
that suspends cells such as erythrocytes, leukocytes, and
thrombocytes and proves to be an ideal ﬂuid for biomarker
inquiry due to its universal availability. Plasma can be iso-
lated from blood by using an anticoagulant and centrifuging
the sample at low speeds. It contains thousands of proteins
that reﬂect the physiological occurrences in the body and
aﬀect the brain from the periphery as well as those proteins
that are exported from the brain. Several studies have been
produced to demonstrate that telomere length in peripheral
bloodcellsareapotentialmarkerforAD,buttherelationship
between peripheral blood leukocyte telomere length and the
proliferation of AD pathogenesis remains unclear. In one
study, the telomere length of peripheral blood leukocytes
was compared to the telomere length in the cerebellum
[9]. Telomere length in the cerebellum was not indicative
of inherited telomere length as a determinant of AD sus-
ceptibility; rather, acquired shortening of peripheral blood
leukocyte telomere lengths could be seen as an indication of
chronicstress,supportinganunderlyingcorrelationbetween
leukocyte telomere length and risk for developing AD.
Urine samples can be considered as a means of diag-
nosing AD through noninvasive procedures. Evaluating the
proteins in urine for AD could help physicians inform
patients of their prognosis. Unfortunately, researchers have
attempted to develop an AD biomarker sensitive enough to
be used on urine, but no such reliable and reproducible
biomarker has been found to date. Early evidence showedInternational Journal of Alzheimer’s Disease 3
increased concentrations of NTP in the urine of AD
patients, generating immense interest among other fellow
biomarker researchers. However, attempts to commercialize
the test were unsuccessful, because the validity of the test
was questioned because of lack of reproducibility. Another
protein called the pancreatic exocrine protein, also known
as pancreatic thread protein (PTP), contained a ﬁbrillary
structure that resembled ﬁbrils located in neuritic plaques in
the brains of AD patients [10]. These researchers observed
extensive amounts of PTP immunoreactivity in the brains of
AD patients. The study found a substantial concentration of
NTP in the CSF of AD patients compared to their controls
[10]. As researchers tried to reproduce the ﬁndings of this
study, they found that PTP was 40 times higher in serum
than in CSF. Furthermore, PTP immunoreactivity in CSF
paralleled with the CSF/serum albumin ratio, which suggests
that NTP in CSF is actually PTP from serum [10].
In particular, the AD-associated neuronal thread protein
(AD7c-NTP) has been of interest as a biomarker due to its
ability to reﬂect signiﬁcant irregularities in cellular function
[9]. Dementia of the AD type is symptomatic of cell loss
that is caused by multiple mechanisms that involve apoptosis
and abnormal mitochondrial function. The AD7c-NTP gene
codes for a protein associated with causing apoptosis and
therefore, the overexpression of the gene could lead to the
celllossseenintheearlystagesofthedisease.Higherlevelsof
AD7c-NTP can be seen in the urine of patients experiencing
early AD and can even oﬀer insight onto the severity of the
dementia. In clinical uses, AD7c-NTP has been shown to be
a very useful biomarker with more than 90% sensitivity for
the early detection of AD [11].
To the contrary, there is much speculation about the
true utility of the NTP and AD7c-NTP. The nucleotide
sequence of AD7c-NTP does not share any resemblance
with a pancreatic thread protein, insinuating that these two
genes code for completely diﬀerent proteins. Additionally,
when the DNA sequence of AD7c-NTP was compared to
chimpanzee and human genomes, various amounts of dif-
ferences were identiﬁed. Coincidentally, these discrepancies
were discovered in places where the human and chimpanzee
genome were completely identical [10].
3. Genomics
The use of genomic technologies is valuable in identify-
ing potential biomarkers in several neurological diseases,
including Alzheimer’s, and promises to provide important
insight for the future in terms of personalized diagnosis
and treatment based on an individuals’ predisposition to a
particular condition. As the genetic analysis of individuals
uncovers heritable risk factors, genomic technologies will
lead to a better understanding of the protein products and
mechanistic pathways associated with the proliferation of the
disease.
One of the ways to ﬁnding potentially useful diagnostic
biomarkers is through genomics and the human genome,
which allows us to better understand disease and the manner
in which it proliferates. Mendelian genetic approaches have
limited utility in identifying neurodegenerative aﬄictions
like AD, because familial cases account for a rather small
amount of those aﬄicted. It is more important to discover
biomarkers that can help explain the more common spo-
radic cases of the disease. Among the inheritable aspects
of Alzheimer’s, apolipoprotein ε4 has been established to
have a particularly strong correlation to the development
of the disease. While single allele diﬀerences are rarely
able to confer an accurate indication for risk of disease
development, Alzheimer’s disease could be an exception.
Entire genome single-nucleotide polymorphism studies have
been conducted, and they conﬁrm that the ApoE locus is
able to indicate, to a certain extent, the genetic susceptibility
to developing AD [12, 13]. The usefulness of genome-wide
association studies primarily lies in their ability to reveal
susceptibility genes of a disease by uncovering DNA variants
in a large-scale analysis of the human genome. Based on
replication in a large number of studies, the only ﬁrmly
established genetic susceptibility factor for Alzheimer disease
is the ε4a l l e l eo fA p o E[ 14]. While genome-wide association
studies have proven to be useful in detecting variations in
DNA that can potentially be linked to the heritability of
this disease, they cannot provide the biological basis of the
disease.
ApoE is a lipid transport protein that is encoded in a
single gene and exists as three diﬀerent isoforms. Based on
the traditional principles of inheritance, the dosage of the
ApoE alleles, divided into ε2, ε3, and ε4, is strongly related to
the risk for dementia of the Alzheimer’s type at an increasing
frequency with the increase of ε4a l l e l e s[ 15]. Although
the Apo E ε4 allele accounts for only 14% of the general
population, approximately 50% of Alzheimer’s patients
carried the ε4a l l e l e[ 16]. Both Carriers and noncarriers
of the ε4 allele develop Alzheimer’s, evidence suggests that
those without the allele are more likely to show signs of the
disease later [17]. As a key component of very low-density
lipoproteins that is required for cholesterol transport both
centrally and in the periphery, the role of ApoE ε4i nA D
has been related to its eﬀect on the metabolism of cholesterol
[18]. Studies of ApoE polymorphisms demonstrate that the
ε4 allele correlates with an elevation in total and low-density
cholesterol levels and could, therefore, play a negative role in
AD [19]. Conversely, it is suggested that the ApoE ε2 plays a
protective role in the development of AD, lowering risk, and
delaying the onset of the disease [20]. The protective ability
of ε2 can be attributed to the opposite eﬀect on cholesterol
metabolism it has compared to the ε4 allele, namely lower
levels of total and low-density lipoprotein cholesterol [21].
The diﬀerent isoforms are also hypothesized to have
varying eﬀects on amyloid plaque formation and metab-
olism. The ε3 isoform can have an increased binding aﬃnity
to Aβ peptides, thereby allowing for the clearance of Aβ and
prevention of neurotoxic plaque formation [22]. It is further
hypothesized that the neurotoxicity of the Aβ peptides
further contributes to neurodegeneration in the ε4 isoform.
While ApoE ε3 is capable of protecting cells from H2O2-
induced oxidative stress, the ε4 isoform is not as successful at
this task [23]. There are several mechanistic explanations for
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the formation of AD plaques, but a conclusive role requires
further studies to be ﬁrmly established.
Mechanistically, ApoE4 may be responsible for acceler-
ating the degeneration of neurons, and thereby damaging
synaptic stability and causing an earlier onset of dementia.
One of the key contributing factors of ApoE on the develop-
mentofneurologicaldiseaseslike ADis linkedtothemanner
in which it contributes to neuronal repair, remodeling, and
protection. Deleterious insults to neurons could be a result
ofoxidativestress,ischemia,inﬂammation,orotherstressors
associated with aging. ApoE is a contributing factor to the
repair of neurons through its lipid transport function. While
ApoE ε2a n dε3a r ee ﬀective in this process of neuronal cell
maintenance, ε4 has been observed to be less eﬃcient in this
role [24]. This further exacerbates the cognitive decline seen
in AD by aﬀecting neuronal connections. Although ApoE
isoforms have a deﬁnite and striking eﬀect on the clearance
of amyloid-β and cytoskeleton stability, there are no uniﬁed
explanations for the manner in which ApoE4 speciﬁcally
causes a notably increased risk for AD.
Among the other biomarker candidates that have been
uncovered using genomic techniques, growth factor recep-
tor-bound associated binding protein 2 (GAB2) alleles have
beenshowntohaveanimpactonADriskforApoE4carriers.
The GAB2 protein is involved in several important signaling
pathways that could be linked to disease proliferation if
interference with the expression of GAB2 were to occur,
as evidenced by the elevated levels of GAB2 in at-risk
neurons and GAB2 proteins found in neuroﬁbrillary tangles
[25]. One study examined the possibility of GAB2 as a
modifying factor for Alzheimer’s risk in ApoE4 carriers
and determined a signiﬁcant correlation between multiple
single-nucleotide polymorphisms (SNPs) and an increased
risk of disease for ε4a l l e l ec a r r i e r s .T h es t u d yu t i l i z e da
genome-wide analysis of 502,627 SNPs to characterize and
determine susceptibility genes for the onset of AD. Through
their surveys of these single-nucleotide polymorphisms, the
researchers determined an association of AD with six single-
nucleotide polymorphisms found in the GAB2 gene as
well as a shared haplotype that encompassed the GAB2
gene. Additionally, it was determined that interference with
the expression of normal GAB2 led to an increase in tau
phosphorylation, which is typically observed in individuals
with AD. Another study further investigated the hypothesis
that normally GAB2 protein is associated with reducing tau
phosphorylationandtheformationofneuroﬁbrillarytangles
and that an isoform of the protein could play a part in
increasing the susceptibility to phosphorylated tau in at-
risk individuals [26]. Further replication of both studies is
required, but it does provide important insight into the
possibilities to better understand the pathogenesis of this
disease that could later contribute to diagnosis and treat-
ment.
Another valuable genomics marker the ApoE gene
indicated that a set of single-nucleotide polymorphisms in
TOMM40, which is located approximately 15Kb upstream
of ApoE, revealed a linkage disequilibrium in connection
with the E4 allele and demonstrated a signiﬁcant associ-
ation to increased AD risk [27]. This particular gene is
responsible for the formation of an essential mitochondrial
membrane protein that plays an active role in protein
transport. Since aberrations in mitochondrial structure or
causes for oxidative stress to the mitochondria are linked to
an increase of AD risk, it would be plausible to propose the
TOMM40 as a genetic indicator of risk [28]. The important
genetic ﬁnding associated with TOMM40 predicts the onset
of AD based on the variable length of deoxythymidine
homopolymer (poly-T) on the gene. Due to the high
linkage disequilibrium between TOMM40 and ApoE that
demonstrates an evolutionary relationship between the two
genes, it is possible to note that speciﬁc variants of TOMM40
are closely associated with each of the ApoE alleles [29]. The
very long poly-T variants are categorized as high-risk alleles
and are linked to ApoE ε4 alleles 98% of the time, whereas
the ApoE ε3 variants are subdivided into either very long
or very short. While the ε3 allele was supposedly neutral
for AD development, it is more likely the heterogeneity of
AD age-of-onset seen in the ε3 population was a result of a
linkage of the allele to both very long or very short poly-T
variants [28]. The variable length of TOMM40 is, therefore,
a candidate for helping predict the onset of AD and has the
potential to be a clinical diagnostic tool. Another signiﬁcant
ﬁnding seen through a genome-wide association study was
that overlapping or linked single-nucleotide polymorphisms
across the TOMM40 and ApoE region showed a signiﬁcant
association with cases of sporadic AD [30]. These ﬁnding
warrant further investigation to determine the utility of the
TOMM40 region as a biomarker of AD.
The results ﬁnding both GAB2 and TOMM40 to be
possible genetic indicators of AD require further study and
conﬁrmation; however, the prospects of genotypic analysis
using single-nucleotide polymorphisms at multiple gene
loci provides exciting possibilities for the determination of
diagnostic risk analysis for this and other diseases.
4.Proteomics andProteins
Another approach towards uncovering a potential diagnostic
biomarker for AD relies on a large-scale analysis of proteins
and protein structure that could be used to indicate risk of
cognitive decline. Proteomics involves two main steps: (1)
separate the proteins using multiplex assays and (2) identify
the protein and its origin. The search for novel biomarkers
that can be used diagnostically at early stages of AD have
looked towards proteomic technologies to determine if there
are proteins that can predict disease as well as monitor
progression and response to treatments. Many proteomic
studieshavebeencoordinatedinordertoaccuratelydiagnose
AD but none have emerged as the deﬁnitive method or
cluster of identiﬁable proteins despite early encouraging
results [31].
Recent proteomic analysis has found that Alzheimer’s
patients have a dysfunctional ubiquitin carboxyl-terminal
hydrolase system. The main purpose of this system, which
contains ubiquitin proteasome, is to destroy misfolded pro-
teins.Ubiquitinproteasomeisaproteinthatsafeguardsother
proteins fromunwantedinteractionbetweenproteins. InAD
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and leads to the amassing of many abnormal proteins in the
system. Recent studies claim that the ubiquitin proteosome
is a target of protein oxidation in AD patients, creating
a connection between oxidative stress and Alzheimer’s in
patients [32].
Through studies of AD patients, researchers were able
to ﬁnd high levels (up to 10x the normal amount) of Glial
ﬁbrillary acidic protein (GFAP) in AD patients. Astrocyte
cells of the CNS and has many important functions,
including cell communication and mitosis. The increased
levels of GFAP in AD brains (?) means that the pathway is
overcompensating for its lack of inﬂuence [32].
Among the more prominently studied biomarkers for
AD risk are plasma levels of Aβ42 and Aβ40, but they have
not emerged to have a deﬁnite value as a predictive tool
[33]. The analysis of plasma Aβ40 and 42 levels oﬀers a
noninvasive and inexpensive biomarker, since a key patho-
logical characteristic of Alzheimer’s is Aβ deposition in
senile plaques. Research has indicated that increased levels
of tau and phospho-tau and decreased levels of Aβ42 can
accurately indicate individuals with AD in CSF [1]. If proven
to be a reliable indicator of mild cognitive impairment
and AD, plasma levels of Aβ40 and Aβ42 and the ratio of
Aβ42/Aβ40 could be a valuable biomarker. Mutations of the
amyloid precursor protein (APP), which produces Amyloid
β protein,can result in an increase of Aβ42 and Aβ40 in
patients prior to the onset of the disease [16]. In all AD
patients, regardless of APP mutation, Aβ is found to collect
and form deposits in the brain that lead to the creation of
senile plaques. Since its role has been extensively studied and
is intrinsically linked with AD, there have been therapeutic
eﬀorts to interfere with the production of Aβ and disband
accumulated amyloid deposits. Due to the diﬀerent cell types
that are capable of producing Aβ, it is hard to establish which
cells are most actively contributing to circulating plasma or
the pathways of interchange of amyloid between the brain
and the periphery [4]. While patients with AD certainly had
increased Aβ plasma levels in the brain and skeletal muscles,
it is not yet possible to consider Aβ a biomarker, since the
pathways of the protein and its dispersion and uptake have
yet to be fully understood.
There have been several noteworthy attempts to validate
plasma Aβ as a biomarker of AD, but questions as to
their reproducibility hinder veriﬁcation of their ability
to accurately diagnose disease. Autopsy conﬁrmed reports
illustrate the prevalence of Aβ42 deposits in AD patients
as either having it be the only form of amyloid β protein
deposited, being the major form, or simply having large
levels of both Aβ42 and 40 deposited. One study indicated
that while patients who have an elevated Aβ42 levels in the
plasma are more at risk for developing AD, after the onset
of the disease Aβ plasma levels actually decline to possibly
reﬂect the compartmentalization of Aβ peptides in the brain
[34]. Another recent longitudinal study demonstrated that
low plasma levels of Aβ40 and 42 had a correlation to
a rapid decline in cognition. The hypothesis to support
this observation was that an increased deposition of Aβ in
the brain would be reﬂected in a lower Aβ plasma level
[35]. While these studies help explain and predict the rapid
cognitive decline that is seen in the disease, it does not really
elucidate the manner in which plasma levels of Aβ can aﬀect
AD risk and development that would indicate its use as a
biomarker.
A case-cohort study determined that a combination of a
highbase-linelevelofAβ40andlowbase-lineconcentrations
of Aβ42 seemed to correlate with a higher risk of developing
dementia [36]. Another study identiﬁed no individual corre-
lationbetweeneitherbaselineAβ40orAβ42withatransition
from mild cognitive impairment to AD, but the ratio of
Aβ42/Aβ40 did demonstrate a relationship with conversion
to AD [33]. The longitudinal study demonstrated that a
lower Aβ42/Aβ40 ratio was indicative of a greater decline in
patient cognition. Unfortunately, conﬂicting results and the
lackofreproducibilityinstudyﬁndingshavemadeitdiﬃcult
to determine the exact role of Aβ in the determination of AD
diagnosis.
While amyloid β protein has undergone extensive study
in its association with AD risk, there are several other
proteins in the plasma that have been analyzed as potential
biomarkers of the disease. Among the more prominently
CSF-based proteins studied in association with AD is tau
because of the hyperphosphorylation and aggregation of tau
protein that is characteristic of the disease. Tau is a state
marker that is located in neuronal axons. Because tau is a
state marker, increased concentrations of tau in individuals
typically means a higher severity of neuronal degeneration
[1]. An increase in tau in AD patients has been discovered
in many diﬀerent studies. However, other dementias, such
as vascular dementia, can lead to an increase in tau as
well. For these reasons, tau cannot be the sole biomarker
for AD, because an increase in tau points to a number of
diﬀerent diseases [1]. There have yet to be any signiﬁcant
studies investigating a blood-based analysis of this particular
protein and its potential as a peripheral biomarker, but other
plasma proteins have been revealed to be of interest. Studies
using the proteomics approach to biomarker identiﬁcation
have yielded plasma proteins that demonstrate a noteworthy
alteration in levels in AD patients when compared with
controls. One study uncovered that alpha-2-macroglobulin
and complement factor H, which are both evident in senile
plaques, are present in elevated levels in AD plasma, with the
latter only evident in increased levels for AD and not other
types of dementia [37].
Phosphorylated tau protein in CSF is a new advancement
in the search for AD biomarkers. The concentration of
phosphorylated tau directly correlates with the state of tau
in the brain. Unlike tau, concentrations of phosphorylated
tau does not increase after a stroke or any other diseases,
making phosphorylated tau a useful biomarker for AD.
Phosphorylated tau protein in CSF has been seen to have
high speciﬁcity, relative to tau protein for AD. Furthermore,
other diseases, such as Parkinson’s and depression, have
normal concentrations of tau in individuals. Therefore, the
speciﬁcity of phosporylated protein will prove useful since it
will be able to distinguish AD from other types of dementias
[1].
In a study focusing on CSF biomarkers and incipient
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as a biomarker had an 83% speciﬁcity for detection of AD,
while combining tau and phosphorylated tau as a biomarker
yielded in a slightly higher speciﬁcity. Furthermore, T-
tau, (what is this? Total tau), P-tau (what is this? Phosph
tau), and Aβ42 have been proven to be strong markers
for the development of AD in patients with mild cognitive
impairment (MCI). If proven by other studies as well, this
result could have an enormous impact on the design of
clinical trials of patients with MCI. As convincing as these
results may seem, more studies are still required to discover
which combination of potential biomarkers generates the
highest speciﬁcity. To increase speciﬁcity, a longer follow-
up time (preferably more than ﬁve years) is required,
because some cases in this study could have developed AD
after the study had completed. Another useful technique in
identifying incipient AD is through neuroimaging methods
and cognitive tests. The downfall to these method is that
each is correlated with disease severity. Trying to detect
incipient AD during the earlier stages would increase the
overlapbetween patientswhoactuallyhaveincipient ADand
patients who have other illnesses [38].
Another potential biomarker that is present in elevated
levels in AD patients is alpha-1-antitrypsin (A1AT), which
can also be found in senile plaques and neuroﬁbrillary
tangles.A1ATisaserineproteaseinhibitorthatisresponsible
forrestrainingoverexpressedproteasesduringinﬂammation.
Therefore, when it is oxidized to its precursor form and
unable to perform this task, there is the characteristic
inﬂammation seen in AD pathology [39]. Another pro-
tein associated with the systemic inﬂammation observed
in the AD patients is the elevated presence of alpha-1-
antichymotrypsin (A1ACT), which is also a serine protease
inhibitor. IncreasesinA1ACT levelshavebeenshowntohave
a correlative relationship with the severity of pathology and
havealsobeenknowntoinducehyperphosphorylationoftau
in neurons [40].
The search for individual plasma biomarkers has yet
to yield a deﬁnitive candidate for the diagnosis of AD.
However, there is the possibility of using multiple protein
markers concurrently to identify the risk for disease. A
recent pilot study demonstrated the potential of 18 diﬀerent
signaling proteins found in the plasma that could be used
as a diagnostic tool. The study observed the alterations in
18 signaling proteins that could indicate changes in the
periphery or central nervous system that are closely linked
to Alzheimer’s disease [41]. When a study was conducted
to reproduce AD diagnosis using the 18 analyte panel, the
attempt was unable to produce similar results. The study was
able to indicate that a full 89-analyte panel might be useful
in diagnosis when used concurrently with other predictive
m a r k e r ss u c ha sA β [42].
The utility of these and other plasma proteins as
diagnostic biomarkers is evident through their accessibility
and ability to indicate several pathological processes that
a r ec h a r a c t e r i s t i c a l l ys e e ni nA D .T h ed i ﬀerences in levels
of plasma proteins between AD patients and controls does
aid in the explanation of disease proliferation, but there
needs to be further work done in this area to deﬁnitively
demonstrate the diagnostic eﬃcacy and reproducibility of
these ﬁndings. Additionally, the requirements of a biomarker
t ob ea b l et os e r v ea sad i a g n o s t i ct o o la sw e l la st od e t e r m i n e
disease progression and the eﬀectsoftreatmentmakeitmore
realistic to work towards establishing a coordinative plasma
biomarker that relies on a combination of diﬀerent markers
to establish AD prognosis and treatment.
5.Epigenetics
Epigenetics is another ﬁeld of study that relies primarily
on the epigenetic regulation of pathology in AD to help
elucidate potential biomarker candidates for the disease. The
term epigenetics refers to the dynamic regulation in genomic
functions that occur independently of DNA sequence and
the modiﬁcation of DNA and chromatin that leads to key
characteristic aberrations of the disease. Abnormalities in
the amyloid precursor protein, Aβ, and the hyperphospho-
rylation are implicated in the pathogenesis of AD, and it
is plausible that alterations in these genes contribute to
the pathways of the disease. By altering the structure of
chromatin, and thereby the transcription and expression of
the genes, epigenetic processes are capable of altering cellular
function. The primary targets of epigenetic regulation are
methylation and histone modiﬁcation of the chromatin;
therefore, technologies to determine DNA methylation and
histone modiﬁcation proﬁles could prove particularly useful
in determining genetic variations and genes responsible for
the proliferation of AD. Additionally, critical changes are
projected to be in epigenetic structures occurring during
progression of the disease, leading to signiﬁcant alterations
inthemolecularstructureofseveralcells,tissues,andorgans.
The transmembrane protein amyloid precursor protein
(APP) has been extensively investigated through an epige-
netics perspective. There are several studies that support
the notion that the abnormalities of epigenetic mechanisms
could aﬀect the expression of APP, which plays an essential
role in controlling Aβ synthesis and formation of plaques.
An earlier study showed that the APP gene was in fact
controlled by methylation and determined that variations in
methylation-inducedAPPexpressionindiﬀerentpartsofthe
brain and other tissues. The determination that alterations
in the methylation of the APP gene directly inﬂuence its
expression in a region-speciﬁc manner suggests that the
changes seen in AD could be impacted by epigenetics.
The role of DNA methylation in AD proliferation has
alsobeenstudiedthroughtheanalysisofhumanpostmortem
braintissuesandthemethylationstatusofvariouspromoters
of genes that are closely linked to the pathology of AD.
One study of the human cerebral cortex demonstrated an
elevation in the methylation of the SORBS3 gene and a
decrease in the methylation of S100A2 gene [43]. The former
is responsible for encoding a cell adhesion molecule that
is seen in neurons and glia, while the latter is a calcium-
bindingprotein.Whilethesealterationsinmethylationstatus
are normally seen in nondemented aging, the shift was much
more evident in AD patients. Another study demonstrated
that the promoter regions of the apolipoprotein E (APOE)
and(MTHFR)geneswerehypermethylatedinADpatientsin
comparison to normal controls [44]. These and other studiesInternational Journal of Alzheimer’s Disease 7
demonstrate the notion that abnormal methylation of genes
could certainly have a pronounced eﬀect in AD.
The aberrations in methylation and other epigenetic
changes seen in AD demonstrate the need to further investi-
gate this approach to AD pathology in order to elucidate the
function of epigenetic regulation in this disease.
6. Metabolomics
Oneofthemorenovelapproachestodiscoveringadiagnostic
biomarker for Alzheimer’s is the study of metabolomics,
which utilizes the science behind biochemistry to detect
any metabolic disruptions by simultaneously monitoring
activity of various metabolites. Any unusual disturbances to
activity in the metabolic network could be useful to better
understanding the mechanisms of the disease. Although
there has yet to be conclusive evidence to illustrate the
existence of a metabolomic ﬁngerprint that could serve as
a conclusive diagnostic biomarker, this new ﬁeld is able to
make signiﬁcant progress by creating a comprehensive map
ofmetabolicpathwayregulationsthatareinﬂuencedbygenes
and the environment.
A recent pilot study probed the viability of utilizing
this technology to better understand mechanistic pathways
and possibly distinguish candidate biomarkers that could
undergo further inquiry in the future. The study used
postmortem samples of cerebrospinal ﬂuid to attempt to
discover any alterations in the metabolic pathways of AD
patients and nondemented subjects. There were signiﬁcant
diﬀerence changes of tyrosine, norepinephrine tryptophan,
purine, and tocopherol pathways in the AD samples when
compared to controls [40]. Since the primary aim was to
establish the practicability of this ﬁeld and its potential to
elucidate biochemical alterations of interest, there have yet to
be any conclusive biomarkers yielded through this approach.
Additionally,thestudywasperformedoncerebrospinalﬂuid,
but peripheral metabolomic signatures for AD compared
to controls and other disease has not yet been explored.
However, this form of exhaustive biochemical analysis could
establish unique perspective on the pathways that are
modiﬁed in disorders like AD that could further ascertain
useful diagnostic markers.
7. Conclusion
The neurodegenerative pathology of Alzheimer’s disease is
the cause for the most prominent form of dementia and
aﬀectsmillionsofpeopleworldwide.Whilethereareimaging
and CSF-based technologies for the detection of this disease,
it is important to inquire into other peripheral biomarkers
that could oﬀer a diagnosis that is both noninvasive and
inexpensive.
Our review has shown that a wide variety of peripheral
biomarkers have been examined. Although all are easily
obtained, they vary in their ability to detect already diag-
noseddisease.Wesuggestthatbiomarkersthatarelessableto
detect already diagnosed disease with minimal error are not
promising candidates for early detection of disease. In view
of the promise of these selected peripheral biomarkers, we
suggest that eﬀort be devoted to determining their eﬃcacy
in large number of persons from a variety of populations.
In addition, it is also essential that peripheral biomarkers
that oﬀer promise in terms of their ability to detect already
diagnosed disease in large populations need to addition-
ally demonstrate their ability to predict future diagnosis
of AD by suﬃc i e n tn u m b e ro fy e a r st oa l l o we ﬀective
intervention.
Establishing the utility of a peripheral biomarker may be
considered in two phases. In Phase 1, it will be necessary to
establish that the biomarker under consideration can detect
already diagnosed AD. In Phase II, it will be necessary to
demonstrate the ability of the biomarker to detect disease
well in advance of the appearance of the current criteria for a
diagnosis of AD.
The approaches reviewed oﬀer important insight into
the groundwork that has been established towards better
comprehending the disease as well as newer ﬁelds of inves-
tigation that oﬀer promising possibilities. These peripheral
biomarkers not only oﬀer the potential to establish diagnos-
tic tools for clinical use, but also lay the foundation for better
understanding the mechanisms of the disease that could
reveal methods for the treatment and even the prevention of
AD.
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